Craft

Veloxis Pharmaceuticals

Revenue

KR39.5 M

FY, 2018

Veloxis Pharmaceuticals Summary

Company Summary

Overview
Veloxis Pharmaceuticals is a biopharmaceutical company, which identifies, develops, and commercializes products that are used in transplantation and adjacent therapies. The Company's patented delivery technology, MeltDose, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis's lead product candidate is Envarsus XR, a once-daily dosage tablet version of tacrolimus, which is used to aid in the prophylaxis of organ rejection in transplant recipients.
Type
Public
Status
Active
Founded
2002
HQ
København, DK | view all locations
Website
http://www.veloxis.com/
Cybersecurity rating
Sectors

Key People

  • Masaya Etoh, Chairman

    • Ira Duarte

      Ira Duarte, Chief Financial Officer

    • Daisuke Matsuo, Board Member

      • Ulf Meier-Kriesche

        Ulf Meier-Kriesche, Chief Scientific Officer

      LocationsView all

      3 locations detected

      • København HQ

        Denmark

        37 Amerika Pl.

      • Cary, NC

        United States

        1001 Winstead Dr #310

      • Cary, NC

        United States

        2000 Regency Pkwy #500

      Veloxis Pharmaceuticals Financials

      Summary Financials

      Revenue (Q3, 2019)
      kr21.3M
      Gross profit (Q3, 2019)
      kr17.5M
      Net income (Q3, 2019)
      kr5.5M
      Cash (Q3, 2019)
      kr34.9M
      EBIT (Q3, 2019)
      kr5.7M

      Footer menu